UPR Activators for Cancer Therapy

用于癌症治疗的 UPR 激活剂

基本信息

项目摘要

Project Summary / Abstract The major goal in this application is to evaluate isatin-derived spirocyclic dimers as novel unfolded protein response (UPR) activators in proof-of-concept studies. Despite the dynamic changes in protein levels, protein homeostasis is maintained by a combination of tightly controlled processes which include synthesis, folding, trafficking and degradation. Accumulation of unfolded / misfolded proteins in the ER due to cell intrinsic and / or extrinsic signals results in the activation of UPR, an adaptation mechanism. Failure to resolve this results in irremediable ER stress and triggers UPR mediated programmed cell death. Cell intrinsic situations in cancer such as loss of tumor suppressor gene or oncogene addication result in higher basal UPR levels. Cancer cells maintain the higher basal UPR levels through upregulation of UPR associated proteins. The higher basal UPR levels in cancer cells provides a therapeutic window that can be exploited by UPR activators. This has been attributed to the success of proteasome inhibitors in the treatment of hematological malignancies. Although the success of proteasome inhibitors validates activation of UPR as a therapeutic modality, the need for UPR activators with novel mechanisms of action (MOA) is exemplified by the failure of proteasome inhibitors in patients with solid tumors. In this application we will address the above need by focusing on the development of a UPR activator with a novel MOA. We have identified an isatin-derived spirocyclic dimer (n7) that activates UPR in both normal and cancer cells but selectively induces apoptosis in cancer cells. Here we propose to continue the development of the novel chemical entity n7 through the following specific aims. Aim 1 will focus on characterization of n7 MOA, aim 2 will focus on structure activity relationship through synthesis and evaluation of n7 analogs and aim 3 will assess the efficacy of n7 or an improved UPR activator in in vivo models. Successful completion of the proposed aims will provide critical proof-of-concept for translating isatin-derived spirocyclic dimers as UPR activators.
项目总结/摘要 本申请的主要目的是评价靛红衍生的螺环二聚体作为新的未折叠的 蛋白质反应(UPR)激活剂的概念验证研究。尽管蛋白质水平发生了动态变化, 蛋白质稳态通过严格控制的过程的组合来维持, 折叠、运输和降解。由于细胞内分泌,未折叠/错误折叠蛋白在ER中积累 和/或外部信号导致UPR(一种适应机制)的激活。未能解决这个问题 导致不可补救的ER应激并触发UPR介导的程序性细胞死亡。细胞内在情况 肿瘤如肿瘤抑制基因缺失或癌基因添加导致较高的基础UPR水平。 癌细胞通过上调UPR相关蛋白质来维持较高的基础UPR水平。的 癌细胞中较高的基础UPR水平提供了可被UPR激活剂利用的治疗窗口。 这归因于蛋白酶体抑制剂在治疗血液病中的成功。 恶性肿瘤。虽然蛋白酶体抑制剂的成功验证了UPR作为治疗剂的激活 模式,需要UPR激活剂与新的作用机制(MOA)的失败, 蛋白酶体抑制剂在实体瘤患者中的应用。在本申请中,我们将通过以下方式解决上述需求: 重点在于开发具有新型MOA的UPR活化剂。我们发现了一种靛红衍生物 一种螺环二聚体(n7),在正常细胞和癌细胞中激活UPR,但在癌细胞中选择性诱导凋亡。 癌细胞在此,我们建议通过以下方法继续开发新的化学实体n7: 具体目标。目标1将侧重于n7 MOA的表征,目标2将侧重于结构活性 通过N7类似物的合成和评价的关系和AIM 3将评估N7或AN的功效 在体内模型中改善UPR激活剂。成功完成拟议目标将为 用于翻译靛红衍生的螺环二聚体作为UPR活化剂的概念验证。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Amarnath Natarajan其他文献

Amarnath Natarajan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Amarnath Natarajan', 18)}}的其他基金

UPR Activators for Cancer Therapy
用于癌症治疗的 UPR 激活剂
  • 批准号:
    10357411
  • 财政年份:
    2022
  • 资助金额:
    $ 34.41万
  • 项目类别:
PROTACs for pancreatic cancer therapy
PROTAC 用于胰腺癌治疗
  • 批准号:
    10027631
  • 财政年份:
    2020
  • 资助金额:
    $ 34.41万
  • 项目类别:
Probes, Inhibitors, and PROTACs (PIP) Core
探针、抑制剂和 PROTAC (PIP) 核心
  • 批准号:
    10714240
  • 财政年份:
    2018
  • 资助金额:
    $ 34.41万
  • 项目类别:
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers
基于喹喔啉的 IKKbeta 抑制剂的开发,用于治疗 Kras 驱动的癌症
  • 批准号:
    10731443
  • 财政年份:
    2016
  • 资助金额:
    $ 34.41万
  • 项目类别:
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers
基于喹喔啉的 IKKbeta 抑制剂的开发,用于治疗 Kras 驱动的癌症
  • 批准号:
    9271163
  • 财政年份:
    2016
  • 资助金额:
    $ 34.41万
  • 项目类别:
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers
基于喹喔啉的 IKKbeta 抑制剂的开发,用于治疗 Kras 驱动的癌症
  • 批准号:
    9920109
  • 财政年份:
    2016
  • 资助金额:
    $ 34.41万
  • 项目类别:
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers
基于喹喔啉的 IKKbeta 抑制剂的开发,用于治疗 Kras 驱动的癌症
  • 批准号:
    9102393
  • 财政年份:
    2016
  • 资助金额:
    $ 34.41万
  • 项目类别:
Phosphorylated Form of Activated IKKbeta and Pancreatic Cancer
磷酸化形式的活化 IKKbeta 与胰腺癌
  • 批准号:
    8907404
  • 财政年份:
    2014
  • 资助金额:
    $ 34.41万
  • 项目类别:
Phosphorylated Form of Activated IKKbeta and Pancreatic Cancer
磷酸化形式的活化 IKKbeta 与胰腺癌
  • 批准号:
    8622788
  • 财政年份:
    2014
  • 资助金额:
    $ 34.41万
  • 项目类别:
Phosphorylated Form of Activated IKKbeta and Pancreatic Cancer
磷酸化形式的活化 IKKbeta 与胰腺癌
  • 批准号:
    8777952
  • 财政年份:
    2014
  • 资助金额:
    $ 34.41万
  • 项目类别:

相似海外基金

Reactions of Alkynes with Metal-Coordinated Phosphenium Ions
炔烃与金属配位磷离子的反应
  • 批准号:
    573824-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 34.41万
  • 项目类别:
    University Undergraduate Student Research Awards
Exploring the missing reactivity of heteroatom-substituted alkynes
探索杂原子取代的炔烃缺失的反应性
  • 批准号:
    559671-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 34.41万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
LEAPS-MPS: Developing a Spectroscopic Map for Terminal Alkynes
LEAPS-MPS:开发末端炔烃的光谱图
  • 批准号:
    2213339
  • 财政年份:
    2022
  • 资助金额:
    $ 34.41万
  • 项目类别:
    Standard Grant
Development of Synthetic Methods for Hetero-fused pi-Conjugated Compounds Based on Trans-Addition to Alkynes
基于炔烃反式加成的异稠合π共轭化合物的合成方法研究进展
  • 批准号:
    21K05061
  • 财政年份:
    2021
  • 资助金额:
    $ 34.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of Enantioselective Carboalumination of Alkenes and Alkynes Catalyzed by Rare-Erath Metal Catalysts
稀土金属催化剂催化烯烃和炔烃对映选择性碳铝化反应的研究进展
  • 批准号:
    21F21334
  • 财政年份:
    2021
  • 资助金额:
    $ 34.41万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Highly Selective Catalytic Reactions of Alkenes and Alkynes Relevant to Medicinal and Process Chemistry
与医药和工艺化学相关的烯烃和炔烃的高选择性催化反应
  • 批准号:
    10544730
  • 财政年份:
    2021
  • 资助金额:
    $ 34.41万
  • 项目类别:
Highly Selective Catalytic Reactions of Alkenes and Alkynes Relevant to Medicinal and Process Chemistry
与医药和工艺化学相关的烯烃和炔烃的高选择性催化反应
  • 批准号:
    10320911
  • 财政年份:
    2021
  • 资助金额:
    $ 34.41万
  • 项目类别:
Development of beta-carbon elimination reactions of alkynes from unstrained vinyl complexes
无应变乙烯基配合物中炔烃的β-碳消除反应的进展
  • 批准号:
    21K05101
  • 财政年份:
    2021
  • 资助金额:
    $ 34.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Reactions of Alkynes with Metal-Coordinated Phosphenium Ions
炔烃与金属配位磷离子的反应
  • 批准号:
    563146-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 34.41万
  • 项目类别:
    University Undergraduate Student Research Awards
Highly Selective Catalytic Reactions of Alkenes and Alkynes Relevant to Medicinal and Process Chemistry
与医药和工艺化学相关的烯烃和炔烃的高选择性催化反应
  • 批准号:
    10581995
  • 财政年份:
    2021
  • 资助金额:
    $ 34.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了